10x Genomics, Inc.
NASDAQ:TXGMedical - Healthcare Information Services
+$2.49 today
- Market cap
- $6.93B
- Beta
- 2.11
- P/E (TTM)
- -196.0
- EPS (TTM)
- -$0.18
Volume 2.10M
Average 3.06M
TXG Net Income
Bottom-line profit, the starting point for calculating cash from operations.
10x Genomics, Inc.NASDAQ: TXG
Net Income · Q2 FY2026 · quarter ended Jun 2026
Net income turns negative
Q2 FY2026 net income was -$17.93M, compared with $34.54M a year earlier. Trailing-twelve-month net income was -$75.13M. Over 3 fiscal years it compounded at -36.0% a year.
Context
- Net income amounted to 6.8% of revenue in FY2025, down 23.1 pp from a year earlier.
- Net income grew in size in 1 of the last 3 fiscal years.
- FY2025 was the smallest annual figure in the 4 fiscal years shown.
What to watch
Whether net income reaches the consensus estimate from 11 analysts of -$79.83M (+83.3%) for the fiscal year ending Dec 2026, a step up from the -76.2% reported in FY2025.
Sources:Cash Flow Analyst consensus estimates Text generated from reported figures; not investment advice.
- Latest quarterJun 2026
- -$17.93M+33.1% QoQ
- Last fiscal yearDec 2025
- -$43.54M-76.2% YoY
- LTMJun 2026
- -$75.13M-11.2% YoY
| Horizon | Past | Forecast | Difference |
|---|---|---|---|
| Quarter | -151.9% | +27.1% | +179.0 pp |
| 1 year | -76.2% | +83.3% | +159.5 pp |
| 3-year CAGR | -36.0% | +6.8% | +42.8 pp |
| 5-year CAGR | — | — | |
| 10-year CAGR | — | — |
Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.
Net Income history
USD · from the cash flow
- Latest · FY2025
- (43.54M) USD
- Year-over-year change
- +76.2%
| Period | Period end | Net Income | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | (43.54M) | +76.2% |
| FY2024 | 2024-12-31 | (182.63M) | +28.4% |
| FY2023 | 2023-12-31 | (255.1M) | -53.7% |
| FY2022 | 2022-12-31 | (166M) | -185.1% |
| FY2021 | 2021-12-31 | (58.22M) | — |
Net Income vs competitors
How TXG compares with its peers on the latest reported figures
- TXG's LTM Jun 2026 net income of $75.13M is the smallest of the 9 companies compared; the peer median is $205.59M.
- Its year-over-year change of -11.2% is the 7th highest of 9, against a peer median of +27.4%.
- Net income amounts to 12.2% of revenue for TXG, versus a peer median of 16.7%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Jul 2026 | $1.44B | +18.0% | -29.8% | 19.5% | |
| LTM Jun 2026 | $484M | -45.7% | — | 10.8% | |
| LTM Jun 2026 | $409.32M | +9.6% | +0.1% | 19.5% | |
| LTM Jul 2026 | $239.22M | -14.2% | -22.2% | 8.2% | |
| LTM Sep 2026 | $171.97M | +120.5% | -14.0% | 14.0% | |
| LTM Jun 2026 | $162.3M | +36.7% | — | 6.3% | |
| LTM Sep 2026 | $130.2M | +67.6% | -14.0% | 28.3% | |
| LTM Mar 2026 | $78.21M | +158.9% | -26.7% | 90.7% | |
| LTM Jun 2026 | $75.13M | -11.2% | -36.0% | 12.2% | |
| Peer median (excluding TXG) | $205.59M | +27.4% | -18.1% | 16.7% | |
Competitors are the stored peer set for TXG. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Cash Flow Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Net Income | (58.22M) | (166M) | (255.1M) | (182.63M) | (43.54M) |
| Depreciation & Amortization | 28.25M | 33.01M | 43.62M | 43.71M | 43.82M |
| Deferred Income Tax | 0 | 0 | 0 | 0 | 0 |
| Stock-Based Compensation | 95.96M | 136.85M | 166.95M | 140.75M | 109.12M |
| Change in Working Capital | (87.45M) | (39.42M) | 17.34M | 1.25M | 24.94M |
| Accounts Receivables | (34.04M) | (18.95M) | (10.61M) | 26.95M | 6.44M |
| Inventory | (30.13M) | (21.19M) | 7.87M | (9.78M) | 27.95M |
| Accounts Payables | 11.08M | 5.86M | (6.02M) | (3.35M) | (2.13M) |
| Other Working Capital | (34.36M) | (5.14M) | 26.1M | (12.57M) | (7.33M) |
| Other Non-Cash Items | 79K | 1.96M | 11.99M | 3.58M | 1.72M |
| Operating Cash Flow | (21.37M) | (33.61M) | (15.2M) | 6.66M | 136.05M |
| Capital Expenditures | (101.28M) | (131.66M) | (49.52M) | (12.39M) | (5.94M) |
| Acquisitions (Net) | (5.45M) | (4M) | 0 | 0 | (9.27M) |
| Purchases of Investments | 0 | (282.87M) | 0 | (48.88M) | (123.44M) |
| Sales of Investments | 0 | 67.65M | 183.02M | 29.64M | 125.2M |
| Other Investing Activities | 0 | 0 | (923K) | (1M) | 0 |
| Investing Cash Flow | (106.73M) | (350.89M) | 133.49M | (32.63M) | (13.44M) |
| Debt Repayment | (5.03M) | (5.41M) | (5.81M) | 0 | 0 |
| Common Stock Issued | 40.33M | 21.23M | 19.48M | 10.91M | 6.8M |
| Common Stock Repurchased | 0 | 0 | 0 | 0 | 0 |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 |
| Other Financing Activities | 0 | 0 | 0 | 0 | 0 |
| Financing Cash Flow | 35.3M | 15.82M | 13.67M | 10.91M | 6.8M |
| Effect of Forex Changes | 234K | (44K) | (33K) | (164K) | 484K |
| Net Change in Cash | (92.57M) | (368.72M) | 131.93M | (15.22M) | 129.9M |
| Free Cash Flow | (122.65M) | (165.27M) | (64.72M) | (5.73M) | 130.12M |
10x Genomics, Inc.
NASDAQ:TXG
Intrinsic Alpha fair value
Locked
Current Price
$57.07
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.